-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates
-
-
-
-
-
-
-
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
-
-
-
-
-
-
-
Halozyme completes $750 million Elektrofi acquisition
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Tops Q3 EPS by 11c, provides guidance
-
-
-
-
-
-
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $72 at H.C. Wainwright
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Confirms Proposal to Combine with Evotec (EVO) for €11.00 Per Share in an All-Cash Transaction
-
1,216,195 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

